Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AK146D1 + Cadonilimab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AK146D1 | AK146-D1|AK-146D1|AK 146D1 | TROP2 Antibody 20 | Limited information is currently available on AK146D1, a putative bispecific antibody-drug conjugate (ADC) targeting Trop2 and Nectin4 (Jul 2025). | |
| Cadonilimab | AK-104|AK 104|AK104 | CTLA4 Antibody 34 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 141 | Cadonilimab is a bispecific antibody that targets CD274 (PD-L1) and CTLA-4, potentially resulting in enhanced anti-tumor immune response (PMID: 36872527). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06929663 | Phase I | AK146D1 + Ivonescimab AK146D1 AK146D1 + Cadonilimab | A Study of AK146D1 as Monotherapy and in Combination With AK104 or AK112, in the Treatment of Advanced Solid Tumors | Recruiting | AUS | 0 |